Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment
THURSDAY, July 14, 2022 (HealthDay News) -- The asthma drug fluticasone furoate is yet another medication that does not work for mild-to-moderate COVID-19, a new study finds. The study was published online July 13 in medRxiv, which publishes studies before they have been peer-reviewed.
"There was no evidence of improvement in time to recovery or reduction in hospitalizations in participants who took fluticasone furoate versus those who took a placebo," lead researcher Adrian Hernandez, M.D., executive director of the Duke Clinical Research Institute in Durham, North Carolina, said in a Duke news release.
The finding comes from a nationwide study of nearly 5,000 participants that continues to evaluate the potential benefit of existing drugs to treat mild-to-moderate COVID-19. Fluticasone furoate is one of three U.S. Food and Drug Administration-approved repurposed medications currently being tested against COVID-19.
Fluticasone furoate is an inhaled corticosteroid used to treat asthma, but it is not approved to treat COVID-19. This drug was tested because corticosteroids had seemed potentially beneficial for treating COVID-19 among nonhospitalized patients. Based on the findings, fluticasone furoate should not be used to treat COVID-19, the researchers stressed.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia
WEDNESDAY, Sept. 20, 2023 (HealthDay News) -- For patients with chronic...
Extremely Low Incidence of COVID Hospitalization After Vaccine, Boosters: Study
FRIDAY, Oct. 7, 2022 (HealthDay News) -- Getting vaccinated and boosted greatly...
Does Exercise Really Help Your Brain? Jury Still Out
MONDAY, March 27, 2023 (HealthDay News) -- It’s long been thought that working...
Recommendations Issued for Medical Response to Mass Shootings
WEDNESDAY, Aug. 3, 2022 (HealthDay News) -- In an article published online July...